HCC4006細胞
數(shù)量： 大量
細胞形態(tài)： 上皮樣
生長狀態(tài)： 貼壁生長
ATCC Number： CRL-2871?
運輸方式： 凍存運輸
相關(guān)**： 腺癌
年限： greater than 50 years *****
器官來源： 肺
細胞類型： 上皮細胞
是否是腫瘤細胞： 0
物種來源： 人
Designations: HCC4006
HCC4006細胞Depositors: JD Minna, AF Gazdar
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: adherent
Organism: Homo sapiens
Morphology: epithelial
Source: Organ: lung
Disease: adenocarcinoma
Derived from metastatic site: pleural effusion
Cell Type: epithelial
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: HCC4006細胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.
Isolation: Isolation date: April 8, 2004
Age: greater than 50 years *****
Gender: male
Ethnicity: Caucasian
Comments: HCC4006細胞This lung adenocarcinoma has an acquired mutation in the EGFR tyrosine kinase domain (L747 - E749 deletion, A750P).
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: Protocol:
Remove and discard culture medium.
Briefly rinse the cell layer with or 0.25% (w/v) Trypsin - 0.53 mM EDTA solution or Dulbecco?s Phosphate Buffered Saline (D-PBS) to remove all traces of serum that contains trypsin inhibitor.
Add 1.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until the cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
Transfer cell suspension to centrifuge tube and spin at approximately 125 x g for 5 to 10 minutes.
Discard supernatant and resuspend cells in fresh growth medium. HCC4006細胞Add appropriate aliquots of cell suspension to new culture vessels. An inoculum of 5 X 10(3) to 7 X 10(3) viable cells/sq. cm is recommended.
Place culture vessels in incubators at 37C. Maintain cultures at a cell concentration between 1 X 10(4) and 3 X 10(4) cells/sq. cm.
Subcultivation Ratio: A subcultivation ratio of 1:4 to 1:6 is recommended
Medium Renewal: Every 2 to 3 days
Preservation: Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Doubling Time: 41 hours
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium): ATCC 30-2001
recommended serum: ATCC 30-2020
0.25% (w/v) Trypsin - 0.53 mM EDTA in Hank' BSS (w/o Ca++, Mg++): ATCC 30-2101
phosphate-buffered saline: ATCC 30-2200
Cell culture tested DMSO: HCC4006細胞ATCC 4-X
References: 90778: Shigematsu H, et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65: 1642-1646, 2005. PubMed: 15753357
